Dr. Jennifer Chan Shares an Important Update about the CABINET Trial

Описание: Dr. Jennifer Chan from Dana Farber Cancer Institute shared the CABINET trial data that showed cabozantinib (CABOMETYX®) helped those with advanced pancreatic NET and extra pancreatic NET (NET outside the pancreas). The results suggest that cabozantinib may be an effective option to treat NET patients, even those who have already tried other therapies. The NET patient community can be hopeful that there will likely be another FDA-approved oral treatment available in the near future.

Click here to read the detailed results of the CABINET trial announcement (https://www.businesswire.com/news/hom...) or the OncLive article here (https://www.onclive.com/view/cabozant....

Watch this exclusive video interview below with Dr. Jennifer Chan at ESMO - European Society for Medical Oncology 2023 in Madrid, Spain.